Medidata Leaders to Share Best Practices on Decentralized Trials, Patient Centricity, and Adaptive Trial Design at DIA Annual Meeting

New York – June 15, 2022 – Medidata, a Dassault Systèmes company, will be leading an innovative educational workshop on how to master decentralized clinical trials (DCTs), sessions on risk-based monitoring and adaptive designs, and more as a premium sponsor of the DIA (Drug Information Association) Global Annual Meeting, June 19-23. Medidata experts will also be participating in multiple presentations and panels covering a range of innovative solutions to advance clinical trial planning, management, and operations.

“The patient focus and collaborative environment of the DIA Annual Meeting is more important than ever, as we use decentralized trials to bring opportunities to more diverse groups and focus on patient needs,” said Jackie Kent, chief customer officer at Medidata. “We’re excited to participate in multiple events with a wide array of experts and engage in discussions about the latest innovations in DCTs, clinical operations and data management.”

Key Sessions and Panels:

Become a DCT Master: Understanding the Lifecycle of Decentralized Clinical Trials

  • Brian Barnes, senior director, Product Management
  • Holly Robertson, senior director, Advisory Services
  • Michael Tucker, managing partner, Patient Cloud
  • Aryana Hosseinkhani, senior director, Product Marketing, Patient Cloud

Participants will learn some of the foundational elements of designing decentralized clinical trials/hybrid trials, and how these advancements in trial design impact all of the stakeholders involved including the patient, sponsor, and site. At the end of the course, participants will become Medidata certified in Mastering DCTs.


DIAmond Session: Preparing for the Future of Research and Development: 10-Years of Multistakeholder Innovation, Collaboration, and Transformation

  • Jackie Kent, Chief Customer Officer, Medidata and Chair, ACRO (Association of Clinical Research Organizations)

This panel will explore the impact of TransCelerate’s initiatives related to the demands of public health crises and the desire to integrate new data into new evidence generation.


Adaptive Designs Save Time and Money: Regulatory Agencies Accept Them - Why Aren’t They Used More?

  • Marc Kaufman, director, Product Management, RTSM Customer Adoption and Value Realization, Medidata
  • Haneen Mazahreh-Boivert, Chief Executive Officer, Pivot Consulting and Services LLC

Adaptive design trials enable sponsors to fail faster and focus effort on where they succeed. The session will cover the process from protocol design to interim analysis and communication to key stakeholders for adaptations.


Collaboration to Improve Definitions, Nomenclature, KPIs, and Readiness Frameworks for the Adoption of Decentralized Research

  • Alicia Staley, vice president, Patient Engagement

The forum will discuss how alliance priorities are designed to improve the global adoption of decentralized research to improve study access and efficiency.


Risk-Based Monitoring in Clinical Trials: An Evolution of Practices During the COVID Pandemic

  • Brian Barnes, senior director, Product Development - RBQM

This panel will report on a two-year analysis of more than 6,000 clinical trials conducted during the global pandemic. This includes looking at the study-level and surveying how risk-based approaches are being adopted.


Design Thinking: The Empathy Map

  • Nadia Bracken, operational advisor (RBQM), Professional Services

This workshop will teach attendees how to develop and utilize an empathy map. Empathy maps can help teams understand patients and their care circle from their view, giving a valuable perspective when designing protocols and studies for a patient population.


Data and Technology in Clinical Trial

  • Shelley Douros, senior director, Product & Data Analytics Clinical Financial Management

This session will share perspectives and examples of digitally-enabled data processes and how they can accelerate timelines. Utilizing data during the clinical trial budgeting process allows for a strategic and compliant approach to financial management.

Learn more about Medidata’s presence at DIA 2022 on its show page or come visit the team at booth #1631.

Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

About Medidata
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 2,000+ customers and partners access the world's most trusted platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: FR0014003TT8, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at and follow us @Medidata.

About Dassault Systèmes

Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production to achieve a more sustainable world for patients, citizens, and consumers.  Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit

3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systèmes, a French “société européenne” (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries.

Tom Paolella
Senior Director, Corporate Communications & Affairs

Paul Oestreicher
External Communications Director